We believe that it is critical to strengthen the translatability of preclinical assays in order to minimize the cost of drug discovery and the risk of clinical failure of drugs. Our goal is to create a robust and reliable preclinical assay platform that can address every aspect of biology that a drug is likely to face in the clinic and thus strengthen the translatability of pre-clinical outcomes.
We are also committed to reducing extent of animal testing and our efforts are focused towards eliminating and replacing the studies that need to be performed in alternative species with more “human-like” assays that can better predict the behavior and properties of the drug substance.
The Reagene in vitro assay platform comprises a growing battery of assays that are re-engineered to replicate the state of the cell/tissue as encountered by the drug in the patient. By creating a mix of 3 D reconstructed cell systems and customized niche assays with specific conditions, Reagene is making it possible to both reduce the multiplicity of in vitro assays as well as increase the throughput of compounds tested.
The Reagene discovery platform hinges on reconstructed human tissue systems that are 3D printed to mimic the natural systems that are being assayed.
We are creating tiers of assay systems for every step of the Lead Optimization process that bring the candidate drugs closer to the biology that they will finally encounter in human.
We do this with the help of a proprietary combination of carefully selected cell types in a layer-on-layer format with an extra-cellular matrix that mimic conditions, both physiological or pathological, in live organisms.